

Tolerability and Safety of Lasmiditan Treatment in Elderly Analyses From Randomized Studies

Clinical Therapeutics

43, 1066-1078

DOI: [10.1016/j.clinthera.2021.04.004](https://doi.org/10.1016/j.clinthera.2021.04.004)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab. <i>Pharmaceuticals</i> , 2021, 14, 924.	1.7	5
2	Cardiovascular Disease and Migraine: Are the New Treatments Safe?. <i>Current Pain and Headache Reports</i> , 0, , .	1.3	7
3	New Oral Drugs for Migraine. <i>CNS Drugs</i> , 2022, 36, 933-949.	2.7	11
4	Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks. <i>Cephalalgia</i> , 2023, 43, 033310242211370.	1.8	8
5	New Migraine Drugs for Older Adults. <i>Drugs and Aging</i> , 2023, 40, 301-305.	1.3	0